第一部分:临床前脓毒症研究的最低质量标准(MQTiPSS)——研究设计与人道建模终点
临床前动物研究是新疗法进入临床试验前的必经步骤,但脓毒症模型因局限性和与临床条件不一致而存在争议。鉴于Sepsis-3修订定义,2017年5月在维也纳召开Wiggers-Bernard会议,对2003至2012年间发表的260篇高被引脓毒症模型文献进行综述,发现79%的研究使用小鼠、仅9%的研究定义了安乐死标准。本报告第一部分详述了脓毒症模型研究设计与人道建模终点的建议:生存随访应反映所用感染原的临床时程、治疗干预应在脓毒症打击后启动以模拟临床诊疗、随机与盲法及完整方法学细节是确定无偏可重复关联的关键、必须实施高标准动物福利并制定疼痛与痛苦监测及安乐死标准、使用镇痛药,并提出四项提升转化潜力的考量(纳入相关生物学变量与合并症、将建模扩展至啮齿类以外的哺乳动物、考虑感染灶的源头控制)。这些建议作为脓毒症动物模型的「最佳实践」提出。
要点
- 生存随访应反映所用感染原的临床时程,治疗干预应在脓毒症打击后启动,以模拟临床诊疗。
- 随机与盲法以及发表时纳入全部方法学细节,是确定新治疗与结局之间无偏、可重复关联的关键。
- 所有临床前脓毒症研究必须实施高标准动物福利,推荐制定并验证疼痛与痛苦监测、脓毒症动物安乐死的具体标准以及使用镇痛药。
- 文献综述显示79%的脓毒症模型研究使用小鼠,仅9%的研究定义了安乐死标准。
- 作者提出四项提升转化潜力的考量:纳入相关生物学变量与合并症、建模扩展至啮齿类以外的哺乳动物、考虑感染灶的源头控制。
适用人群与场景
- 临床前脓毒症动物模型研究,涵盖2003至2012年间发表的260篇高被引脓毒症模型文献所代表的研究场景。
处置流程与药物剂量
- 生存随访应反映所用感染原的临床时程。
- 治疗干预应在脓毒症打击后启动,以模拟临床诊疗。
- 应实施随机与盲法,并在科学发表中纳入全部方法学细节。
- 必须实施高标准动物福利,推荐制定并验证疼痛与痛苦监测及脓毒症动物安乐死的具体标准,并推荐使用镇痛药。
- 研究设计应纳入相关生物学变量与合并症,脓毒症建模应扩展至啮齿类以外的哺乳动物,并应考虑感染灶的源头控制(如存在明确的感染焦点)。
研究设计与关键结果
- 2017年5月在维也纳召开Wiggers-Bernard会议,对2003至2012年间发表的260篇高被引脓毒症模型文献进行综述,发现79%的研究使用小鼠、9%的研究定义了安乐死标准。
- 报告第一部分提出脓毒症模型研究设计与人道建模终点的建议,包括生存随访反映感染原临床时程、治疗在脓毒症打击后启动、随机与盲法、高标准动物福利与安乐死标准、以及四项提升转化潜力的考量。
证据类型、等级与局限
- 证据类型:会议共识报告(Wiggers-Bernard会议),基于对260篇高被引脓毒症模型文献的综述。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者提出这些建议和考量作为脓毒症动物模型的「最佳实践」,应予实施。
指南或共识出处
- Wiggers-Bernard会议报告第一部分:临床前脓毒症研究的最低质量标准(MQTiPSS),2017年5月于维也纳发布。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Preclinical animal studies are mandatory before new treatments can be tested in clinical trials. However, their use in developing new therapies for sepsis has been controversial because of limitations of the models and inconsistencies with the clinical conditions. In consideration of the revised definition for clinical sepsis and septic shock (Sepsis-3), a Wiggers-Bernard Conference was held in Vienna in May 2017 to propose standardized guidelines on preclinical sepsis modeling. The participants conducted a literature review of 260 most highly cited scientific articles on sepsis models published between 2003 and 2012. The review showed, for example, that mice were used in 79% and euthanasia criteria were defined in 9% of the studies. Part I of this report details the recommendations for study design and humane modeling endpoints that should be addressed in sepsis models. The first recommendation is that survival follow-up should reflect the clinical time course of the infectious agent used in the sepsis model. Furthermore, it is recommended that therapeutic interventions should be initiated after the septic insult replicating clinical care. To define an unbiased and reproducible association between a new treatment and outcome, a randomization and blinding of treatments as well as inclusion of all methodological details in scientific publications is essential. In all preclinical sepsis studies, the high standards of animal welfare must be implemented. Therefore, development and validation of specific criteria for monitoring pain and distress, and euthanasia of septic animals, as well as the use of analgesics are recommended. A set of four considerations is also proposed to enhance translation potential of sepsis models. Relevant biological variables and comorbidities should be included in the study design and sepsis modeling should be extended to mammalian species other than rodents. In addition, the need for source control (in case of a defined infection focus) should be considered. These recommendations and considerations are proposed as "best practices" for animal models of sepsis that should be implemented.
参考来源
- Zingarelli B, Coopersmith CM, Drechsler S, et al. Part I: Minimum Quality Threshold in Preclinical Sepsis Studies (MQTiPSS) for Study Design and Humane Modeling Endpoints. Shock. 2019. PMID: 30106874. doi:10.1097/SHK.0000000000001243
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。